Chinese Biotechs' Foray Into mRNA Enters New Chapter With $100m Everest Deal
Executive Summary
Everest Medicines’ deal with Canadian biotech Providence Therapeutics contains a full transfer of technology which may be appealing to Chinese regulators.
You may also be interested in...
China mRNA COVID Vaccines Progress As Shanghai Rolls Out First Inhaled Shot
CanSino’s global-first inhaled COVID-19 vaccine is dosed into its first noses in Shanghai, while Zhejiang Haichang, Everest Medicines and Abogen make major progress with their respective mRNA vaccine programs.
China’s Lead mRNA COVID-19 Vaccine Candidate Faces Phase III Delays
The leader in China's homegrown mRNA COVID-19 vaccine effort expects a delay to key Phase III results, with analysts now expecting to see figures from the international portion of the study in early 2022.
Providence’s COVID-19 mRNA Vaccine Challenger Seen In Phase III In Q1
A possible alternative to Pfizer and Moderna’s COVID-19 vaccines, Providence Therapeutics’ mRNA candidate is seen moving into Phase III trials during the calendar first quarter of next year. While partners Everest Medicines and Biological E have kept the ball rolling, the Canadian biotech will seek further funding, CEO Brad Sorenson tells Scrip in this audio interview.